Radiation dose rates of differentiated thyroid cancer patients after 131I therapy

被引:0
作者
Pingyan Jin
Huijuan Feng
Wei Ouyang
Juqing Wu
Pan Chen
Jing Wang
Yungang Sun
Jialang Xian
Liuhua Huang
机构
[1] The Sixth Affiliated Hospital of Kunming Medical University,Department of Nuclear Medicine, People’s Hospital of Yuxi City
[2] Zhujiang Hospital of Southern Medical University,Department of Nuclear Medicine
来源
Radiation and Environmental Biophysics | 2018年 / 57卷
关键词
Differentiated thyroid cancer (DTC); I treatment; Radiation safety; Radioiodine clearance; Contact time restrictions;
D O I
暂无
中图分类号
学科分类号
摘要
Postoperative 131I treatment for differentiated thyroid cancer (DTC) can create a radiation hazard for nearby persons. The present prospective study aimed to investigate radiation dose rates in 131I-treated DTC patients to provide references for radiation protection. A total of 141 131I-treated DTC patients were enrolled, and grouped into a singular treatment (ST) group and a repeated treatment (RT) group. The radiation dose rate of 131I-treated patients was measured. The rate of achieving discharge compliance and restricted contact time were analyzed based on Chinese regulations. Multivariate logistic regression analysis was used to analyze the independent factors associated with the clearance of radioiodine. The rate of achieving discharge compliance (131I retention < 400 MBq) was 79.8 and 93.7% at day 2 (D2) for the ST and RT groups, respectively, and reached 100% at D7 and D4, respectively. The restricted contact time with 131I-treated patients at 0.5 m for medical staff, caregivers, family members, and the general public ranged from 4 to 7 days. Multivariate logistic regression analysis showed that the 24-h iodine uptake rate was the only significant factor associated with radioiodine clearance. For the radiation safety of 131I-treated DTC patients, the present results can provide radiometric data for radiation protection.
引用
收藏
页码:169 / 177
页数:8
相关论文
共 139 条
[1]  
Asli IN(2010)Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma Radiat Prot Dosim 138 376-381
[2]  
Baharfard N(2015)Radiation safety in the management of patients undergoing radioactive iodine ablation therapy Clin J Oncol Nurs 19 44-46
[3]  
Shafiei B(2009)Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55GBq of (131I) NaI, on an outpatient basis, be safe? Nucl Med Commun 30 533-541
[4]  
Tabei F(2013)The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer Radiat Prot Dosim 156 25-29
[5]  
Javadi H(2009)Molecular pathology of differentiated thyroid cancer Q J Nucl Med 53 440-454
[6]  
Seyedabadi M(2016)2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133
[7]  
Nabipour I(2014)Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy Health Phys 106 466-474
[8]  
Assadi M(2008)Analysis of variance: is there a difference in means and what does it mean? J Surg Res 144 158-170
[9]  
Beck M(2015)Classification and general considerations of thyroid cancer Ann Clin Pathol 3 1045-378
[10]  
de Carvalho JW(2012)Thyroid remnant ablation using 1110MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy Ann Nucl Med 26 370-538